Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
作者： Yuan Hu , Xian-Zhe Dong , Xu Liu , Ping Liu , Yi-Bang Chen
DOI: 10.1021/ACS.MOLPHARMACEUT.5B00927
关键词: EGFR inhibitors 、 Cetuximab 、 Epidermal growth factor receptor 、 Janus kinase 、 Lung cancer 、 JAK-STAT signaling pathway 、 Cell growth 、 Pharmacology 、 Medicine 、 Apoptosis
摘要: Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is effective in the treatment of non-small-cell lung cancers (NSCLCs). However, resistance to EGFR inhibitors limits its effectiveness. In this study, we investigated effectiveness Jak-2 CYT387, combination with cetuximab. Xenograft animal models were administered cetuximab or CYT387 their combination. It was observed that NSCLC cells exhibited enormous differences responses cetuximab; cell lines more intrinsically resistant (H1975 and H1650), efficacy increased when combined whereas alone low doses little effect on proliferation. addition, antitumor activity H1975 model spite in. Jak/STAT signaling suppressed effectively by CYT387. summary, our findings indicated that...
acs.org
sci-hub.se 参考文章(49)
Jéssica Gomes, Marcelo Cruz, Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors. OncoTargets and Therapy. ,vol. 8, pp. 1137- 1142 ,(2015) , 10.2147/OTT.S75388
Erik Teugels, Joanna Vermeij, Jacques De Grève, Lore Decoster, Jan Van Meerbeek, Denis Schallier, [Targeted therapies in the treatment of non-small cell lung cancer]. Bulletin Du Cancer. ,vol. 95, pp. 358- 364 ,(2008) , 10.1684/BDC.2008.0591
Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi, Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma Clinical Cancer Research. ,vol. 22, pp. 426- 435 ,(2016) , 10.1158/1078-0432.CCR-15-0620
Rolf W. Sparidans, Selvi Durmus, Ning Xu, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen, Liquid chromatography–tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma Journal of Chromatography B. ,vol. 895-896, pp. 174- 177 ,(2012) , 10.1016/J.JCHROMB.2012.03.021
Gholamreza Bidkhori, Ali Moeini, Ali Masoudi-Nejad, Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression PLoS ONE. ,vol. 7, pp. e48004- ,(2012) , 10.1371/JOURNAL.PONE.0048004
Antonio Rossi, Paolo Maione, Cesare Gridelli, Cetuximab in advanced non-small cell lung cancer Critical Reviews in Oncology Hematology. ,vol. 59, pp. 139- 149 ,(2006) , 10.1016/J.CRITREVONC.2006.02.006
Taofeek K. Owonikoko, Shi-Yong Sun, Suresh S. Ramalingam, The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer Clinical Lung Cancer. ,vol. 10, pp. 230- 238 ,(2009) , 10.3816/CLC.2009.N.031
Stephen Y. Lai, Faye M. Johnson, Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resistance Updates. ,vol. 13, pp. 67- 78 ,(2010) , 10.1016/J.DRUP.2010.04.001
Shirish M. Gadgeel, The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients Current Oncology Reports. ,vol. 13, pp. 272- 279 ,(2011) , 10.1007/S11912-011-0170-3
Meng Wang, Jing Zhao, Lian-Min Zhang, Hui Li, Jin-Pu Yu, Xiu-Bao Ren, Chang-Li Wang, Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer Journal of Cancer Research and Clinical Oncology. ,vol. 138, pp. 2069- 2077 ,(2012) , 10.1007/S00432-012-1291-2